TABLE 1.—FY 1997 ALLOTMENT—ADMINISTRATION ON DEVELOPMENTAL DISABILITIES—Continued

	State developmental disabilities councils	Percentage
Ohio	2,956,009	4.196611
Oklahoma	919,612	1.305562
Oregon	744,861	1.057470
Pennsylvania	3,208,727	4.555392
Rhode Island	420,475	.596943
South Carolina	1,059,457	1.504099
South Dakota	420,475	.596943
Tennessee	1,476,074	2.095565
Texas	4,531,299	6.433032
Utah	550,178	.781081
Vermont	420,475	.596943
Virginia	1,443,415	2.049199
Washington	1,143,692	1.623686
West Virginia	809,722	1.149553
Wisconsin	1,317,695	1.870716
Wyoming	420,475	.596943
American Samoa	220,750	.313396
Guam	220,750	.313396
Northern Mariana Islands	220,750	.313396
Puerto Rico	2,381,894	3.381547
Palau	110,375	.156698
Virgin Islands	220,750	.313396

TABLE 2.—FY 1997 ALLOTMENT—ADMINISTRATION ON DEVELOPMENTAL DISABILITIES

	Protection & advocacy	Percentage
Total	[1] $25,911,318	100.000000
Alabama	439,048	1.694426
Alaska	254,508	.982227
Arizona	344,561	1.329770
Arkansas	258,072	.995982
California	2,211,563	8.535124
Colorado	276,741	1.068031
Connecticut	260,970	1.007166
Delaware	254,508	.982227
District of Columbia	254,508	.982227
Florida	1,070,357	4.130847
Georgia	603,004	2.327184
Hawaii	254,508	.982227
Idaho	254,508	.982227
Illinois	906,534	3.498602
Indiana	506,712	1.955562
Iowa	264,834	1.022078
Kansas	254,508	.982227
Kentucky	405,708	1.565756
Louisiana	466,720	1.801221
Maine	254,508	.982227
Maryland	341,643	1.318509
Massachusetts	451,170	1.741208
Michigan	833,321	3.216050
Minnesota	357,383	1.379254
Mississippi	315,443	1.217395
Missouri	460,588	1.777555
Montana	254,508	.982227
Nebraska	254,508	.982227
Nevada	254,508	.982227

TABLE 2.—FY 1997 ALLOTMENT—ADMINISTRATION ON DEVELOPMENTAL DISABILITIES—Continued

	Protection & advocacy	Percentage
New Hampshire	254,508	.982227
New Jersey	516,527	1.993442
New Mexico	254,508	.982227
New York	1,384,297	5.342441
North Carolina	635,552	2.452797
North Dakota	254,508	.982227
Ohio	997,392	3.849252
Oklahoma	307,034	1.184942
Oregon	263,782	1.018018
Pennsylvania	1,047,473	4.042531
Rhode Island	254,508	.982227
South Carolina	366,434	1.414185
South Dakota	254,508	.982227
Tennessee	495,147	1.910929
Texas	1,512,208	5.836091
Utah	254,508	.982227
Vermont	254,508	.982227
Virginia	505,699	1.951653
Washington	385,932	1.489434
West Virginia	275,697	1.064002
Wisconsin	448,512	1.730950
Wyoming	254,508	.982227
American Samoa	136,161	.525489
Guam	136,161	.525489
Northern Mariana Islands	136,161	.525489
Puerto Rico	800,722	3.090240
Palau	68,750	.265328
Virgin Islands	136,161	.525489

[1] In accordance with Public Law 103–230, Section 142(c)(5), $806,682 has been withheld for funding technical assistance and American Indian Consortiums in Fiscal Year 1997. The statute provides for spending up to two percent (2%) of the amount appropriated under Section 143 to fund technical assistance. American Indian Consortiums are eligible to receive an alllotment under Section 142(c)(1)(A)(i). Unused funds will be reallotted in accordance with Section 142(c)(1) of the Act.

Dated: March 21, 1996.

Bob Williams,

Commissioner, Administration on Developmental Disabilities.

[FR Doc. 96–7379 Filed 3–26–96; 8:45 am]

BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 96N–0005]

Review of Infant Formula Nutrient Requirements; Announcement of Study; Request for Scientific Data and Information; Announcement of Open Meeting; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of March 5, 1996 (61 FR 8628). The document announced the Federation of American Societies for Experimental Biology (FASEB) study ''Review of Infant Formula Nutrient Requirements,'' requested scientific data and information, and announced an open meeting to be held on May 31, 1996. The location of the open meeting was inadvertently omitted. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Elizabeth A. Yetley, Center for Food Safety and Applied Nutrition, Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–205–4168.

In FR Doc. 95–5117, appearing on page 8628 in the Federal Register of Tuesday, March 5, 1996, the following correction is made:

1. On page 8628, in the first column, under the ADDRESSES caption, the sentence ''The public meeting will be held in the Chen Auditorium, Lee Bldg., FASEB, 9650 Rockville Pike, Bethesda, MD.'' is inserted as the first sentence immediately after the ADDRESSES caption.

Dated: March 20, 1996.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 96–7311 Filed 3–26–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96G–0096]

The Flax Council of Canada; Filing of Petition for Affirmation of GRAS Status

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that The Flax Council of Canada has filed a petition (GRASP 5G0416) proposing to affirm that low linolenic acid flaxseed oil is generally recognized as safe (GRAS) for use as a food oil.

DATES: Written comments by June 10, 1996.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Lawrence J. Lin, Center for Food Safety and Applied Nutrition (HFS–206), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3103.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (secs. 201(s) and 409(b)(5) (21 U.S.C. 321(s) and 348(b)(5)) and the regulations for affirmation of GRAS status in § 170.35 (21 CFR 170.35), notice is given that The Flax Council of Canada, 465–167 Lombard Ave., Winnipeg, MB R3B 0T6, Canada, has filed a petition (GRASP 5G0416) proposing to affirm that low linolenic acid flaxseed oil is GRAS for use as a food oil. The petitioner proposes that solin oil be the common or usual name for low linolenic acid flaxseed oil.

The petition has been placed on display at the Dockets Management Branch (address above).

Any petition that meets the requirements outlined in §§ 170.30 (21 CFR 170.30) and 170.35 is filed by the agency. There is no prefiling review of the adequacy of data to support a GRAS conclusion. Thus, the filing of a petition for GRAS affirmation should not be interpreted as a preliminary indication of suitability for GRAS affirmation.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Interested persons may, on or before June 10, 1996, review the petition and file comments with the Dockets Management Branch (address above). Two copies of any comments should be filed and should be identified with the docket number found in brackets in the heading of this document. Comments should include any available information that would be helpful in determining whether the substance is, or is not, GRAS for the proposed use. In addition, consistent with the regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency encourages public participation by review of and comment on the environmental assessment submitted with the petition that is the subject of this notice. A copy of the petition (including the environmental assessment) and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: March 13, 1996.

Eugene C. Coleman,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 96–7312 Filed 3–26–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 92G–0085]

Michael Foods, Inc.; Withdrawal of GRAS Affirmation Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a petition (GRASP 2G0387) proposing that the use of β-cyclodextrin as a processing aid in reducing the cholesterol content of liquid eggs be affirmed as generally recognized as safe (GRAS).

FOR FURTHER INFORMATION CONTACT: Andrew D. Laumbach, Center for Food Safety and Applied Nutrition (HFS–217), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3071.

SUPPLEMENTARY INFORMATION: In a notice published in the Federal Register of March 30, 1992 (57 FR 10767), FDA announced that a petition (GRASP 2G0387) had been filed by Michael Foods, Inc., 324 Park National Bank Bldg., 5353 Wayzata Blvd., Minneapolis, MN 55416. This petition proposed that the use of β-cyclodextrin as a processing aid in reducing the cholesterol content of liquid eggs be affirmed as GRAS.

Michael Foods, Inc. has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: March 7, 1996.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 96–7310 Filed 3–26–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96N–0095]

Hoffmann-La Roche, Inc., et al.; Withdrawal of Approval of 49 New Drug Applications, 9 Abbreviated Antibiotic Applications, and 36 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 49 new drug applications (NDA's), 9 abbreviated antibiotic applications (AADA's), and 36 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: April 26, 1996.

FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1038.

SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

Application no.	Drug	Applicant
NDA 3–718	Synkayvite Tablets and Injection	Hoffman-La Roche, Inc., 340 Kingsland St., Nutley, NJ 07110.
NDA 3–977	Theelin	Parke-Davis, 2800 Plymouth Rd., Ann Arbor, MI 48105.
NDA 6–071	Berocca Injectable	Hoffman La Roche, Inc.
NDA 6–128	Sopronol Ointment	Wyeth-Ayerst Laboratories, P.O. Box 8299, Philadelphia, PA 19101–8299.
NDA 6–129	Sopronol Solution	Do.
NDA 6–130	Sopronol Powder	Do.
NDA 9–102	Antepar Tablets and Syrup	Burroughs Wellcome Co., 3030 Cornwallis Rd., P.O. Box 12700, Research Triangle Park, NC 27709–2700.